Liposome mediated-CYP1A1 gene silencing nanomedicine prepared using lipid film-coated proliposomes as a potential treatment strategy of lung cancer

Zhang, Mengtian; Wang, Qin; Wan, Ka-Wai; Ahmed, Waqar; Phoenix, David A.; Zhang, Zhirong; Elrayess, Mohamed A.; Elhissi, Abdelbary; Sun, Xun

doi:10.1016/j.ijpharm.2019.04.078

Cited by 20 publications

(9 citation statements)

References 48 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The increase of CYP1A1 activity contributes to the metabolic activation and carcinogenicity of PAHs. The researchers designed a liposome-based CYP1A1 silencing nanomedicine, showing the potential for the treatment of lung cancer (Zhang et al, 2019). CYP1B1 catalyzes the activation of N-nitrosamines such as 4-methylnitrosamino-l-3-pyridyl-butanone (NNK).…”

Section: Differential Expression Of Dmes In Cancermentioning

confidence: 99%

Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer

Wang

Jiang

et al. 2020

Drug Metab Dispos

View full text Add to dashboard Cite

Drug metabolism is a biotransformation process of drugs, catalyzed by drug-metabolizing enzymes (DMEs), including phase I DMEs and phase II DMEs. The aberrant expression of DMEs occurs in the different stages of cancer. It can contribute to the development of cancer and lead to individual variations in drug response by affecting the metabolic process of carcinogen and anticancer drugs. Apart from genetic polymorphisms, which we know the most about, current evidence indicates that epigenetic regulation is also central to the expression of DMEs. This review summarizes differentially expressed DMEs in cancer and related epigenetic changes, including DNA methylation, histone modification, and noncoding RNAs. Exploring the epigenetic regulation of differentially expressed DMEs can provide a basis for implementing individualized and rationalized medication. Meanwhile, it can promote the development of new biomarkers and targets for the diagnosis, treatment, and prognosis of cancer. SIGNIFICANCE STATEMENTThis review summarizes the aberrant expression of DMEs in cancer and the related epigenetic regulation of differentially expressed DMEs. Exploring the epigenetic regulatory mechanism of DMEs in cancer can help us to understand the role of DMEs in cancer progression and chemoresistance. Also, it provides a basis for developing new biomarkers and targets for the diagnosis, treatment, and prognosis of cancer.

show abstract

Section: Differential Expression Of Dmes In Cancermentioning

confidence: 99%

Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer

Wang

Jiang

et al. 2020

Drug Metab Dispos

View full text Add to dashboard Cite

show abstract

“…The study also reported lower adverse events with the CRISPR therapy than a parallel paclitaxel therapy, which further highlights the advantages of this approach. Zhang and co-workers reported inhibition of lung tumor growth in BALB/c nude xenografts upon liposomal administration of anti-CYP1A1 siRNA and leading to the downregulation of CYP1A1 mRNA [123]. In a proof-of-concept study, Moitra and co-workers developed an aptamer-guided pH sensitive liposomal formulation to delivery plasmid DNA as well as siRNA to EpCAM overexpressing cancer stem cells [124].…”

Section: Liposomesmentioning

confidence: 99%

Non-Viral Gene Therapy Vectors for Cancer Treatment

Kanvinde¹,

Kulkarni²,

Deodhar³

et al. 2022

Preprint

View full text Add to dashboard Cite

The research and development of non-viral gene therapy has been extensive over the past decade and has received a big push thanks to the successful approval of non-viral gene therapy products in recent times. Despite these developments, gene therapy applications in cancer have been limited. One of the main causes of this has been the imbalance in development of delivery vectors as compared to nucleic acid payloads. This paper reviews non-viral vectors that can be used to deliver nucleic acids for cancer treatment. It discusses various types of vectors and highlights their current applications. Additionally, it also discusses perspective on regulatory landscape to facilitate commercial translation of gene therapy.

show abstract

“…Here, there are some examples of the recently reported non-viral gene carriers for lung cancer gene therapy [155][156][157][158]. siRNA-encapsulated nanoformulations are being widely examined to find the suitable formulation, for lung cancer treatment [76,159]. For example, CYP1A1 is an important family member of cytochrome P450 enzymes involved in the metabolic pathways of cancer which is highly conserved in lung cancer.…”

Section: Lung Cancer Therapymentioning

confidence: 99%

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Mohammadinejad

Dehshahri

Madamsetty

et al. 2020

Journal of Controlled Release

178

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Liposome mediated-CYP1A1 gene silencing nanomedicine prepared using lipid film-coated proliposomes as a potential treatment strategy of lung cancer

Cited by 20 publications

References 48 publications

Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer

Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer

Non-Viral Gene Therapy Vectors for Cancer Treatment

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Contact Info

Product

Resources

About